

Universal Biosensors, Inc.
ARBN 121 559 993

1 Corporate Avenue
Rowville Victoria 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



3 July 2023

Xprecia business update

Universal Biosensors, Inc. (ASX:UBI) advises the following:

- UBI received the FDA's "Request for Additional Information" in response to the 510K application submitted on 24 March 2023. UBI is in the process of collating the information requested and has until 13 December 2023 to submit its responses in full. UBI expect its responses to be submitted during Q4 and well before the deadline.
- UBI has signed a new distribution deal with EBOS Group Limited for the exclusive sale of Xprecia Stride in Australia and New Zealand. 600 Xprecia Stride devices have been delivered to EBOS and UBI expect sales to exceed AUD \$300,000 per annum once all of the devices are deployed into hospitals, clinics and GP offices across Australia and New Zealand.
- UBI has signed an amended Settlement Agreement with Siemens Healthcare Diagnostics Inc. ("Siemens") whose distribution rights to sell Xprecia Stride ended globally on 31 March 2023. The new terms include an agreement whereby UBI will not pay the AUD \$2.2m (USD \$1.5m) Licence Fee associated with sale of Xprecia in the USA. This Licence Fee has previously been provided for as a liability in the balance sheet and the amount of approximately AUD \$2.2m will be written back to the income statement as revenue during Q2 2023.

End

Enquiries:
John Sharman
Chief Executive Officer
+61 (0) 414 440 680

Announcement authorized by the Board of Directors of Universal Biosensors, Inc.

**About Universal Biosensors**

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. UBI's ambition is to build a multi product stable of biosensors in large markets which generate ongoing revenue streams. For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

About EBOS Group Limited

EBOS Group Limited is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. It is also a leading marketer and distributor of recognised animal care brands. Generating \$10.7 billion in revenue annually across its businesses and servicing thousands of customers across Australasia, EBOS Group is committed to building better communities through an unwavering commitment to the provision of high-quality healthcare and animal care products. With almost 5,000 employees in 109 locations across Australia, New Zealand, and Southeast Asia, EBOS Group positively impacts the lives of millions of people and animals across the communities it serves, every day. EBOS Group is publicly listed on the New Zealand and Australian stock exchanges.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.